P/E ratio for Meridian Bioscience (VIVO)
P/E ratio as of April 2024 (TTM): 35.0
According to Meridian Bioscience's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 35.0206. At the end of 2021 the company had a P/E ratio of 14.8.
P/E ratio history for Meridian Bioscience from 2001 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 14.8 | 28.92% |
| 2020 | 11.5 | -46.01% |
| 2019 | 21.2 | -26.59% |
| 2018 | 28.9 | 7.47% |
| 2017 | 26.9 | 8% |
| 2016 | 24.9 | 5.7% |
| 2015 | 23.6 | 21.8% |
| 2014 | 19.4 | -34.31% |
| 2013 | 29.5 | 25.19% |
| 2012 | 23.5 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Thermo Fisher Scientific TMO | 36.4 | 3.84% | 🇺🇸 USA |
 Becton Dickinson BDX | 42.3 | 20.76% | 🇺🇸 USA |
 Hologic HOLX | 39.8 | 13.54% | 🇺🇸 USA |
 QuidelOrtho QDEL | 207 | 491.79% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.